Stifel raised the firm’s price target on Guardant Health (GH) to $120 from $100 and keeps a Buy rating on the shares. Considering the outlook for 2026, the firm believes Guardant is set up to have a solid year of volume and average selling price growth, with publication and reimbursement catalysts that will “keep investors interested,” the analyst says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $135 from $120 at Mizuho
- Guardant Health price target raised to $130 from $100 at TD Cowen
- RBLX, META, GH, IONS: Cathie Wood Loads Up on Roblox, Trims Meta and Biotech Stocks
- Guardant Health management to meet virtually with BTIG
- TEM, KDK, PSNL: Cathie Wood Loads Up on AI Health Tech, Trims SHOP & ROKU